Photo from ESMO/LinkedIn
Jun 26, 2024, 13:47
177Lu-DOTATATE as a frontline treatment for somatostatin receptor-positive grade 3 low GEP-NETs
ESMO shared on LinkedIn:
“ESMOGI24: Promising data from the phase III NETTER-2 study show that peptide receptor radionuclide therapy significantly improves outcomes for patients with grade 2 high-grade 3 low gastroenteropancreatic neuroendocrine tumours (GEP-NETs), regardless of tumour grade or primary origin.
According to Rocio Garcia-Carbonero, commenting on these results for the ESMO Daily Reporter, this study supports the use of 177Lu-DOTATATE as a frontline treatment for somatostatin receptor-positive grade 3 low GEP-NETs, and possibly selected patients with grade 2 high GEP-NETs.”
Source: ESMO/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 18, 2024, 12:57
Nov 18, 2024, 12:54
Nov 18, 2024, 12:50
Nov 18, 2024, 12:20
Nov 18, 2024, 12:17
Nov 18, 2024, 12:13